BioStock: Lipum presents promising phase I data at ACR 2024

Lipum will present positive data from the phase I study of its drug candidate SOL-116 at the American College of Rheumatology (ACR) Annual Meeting 2024, a leading global conference in rheumatology. The interim results confirm that SOL-116 demonstrates a favourable safety profile and pharmacokinetics in line with expectations. The study approaches its conclusion, and Lipum plans to share the final report in the first quarter of 2025. 

Read the full article at biostock.se:

https://www.biostock.se/en/2024/11/lipum-presents-promising-phase-i-data-at-acr-2024/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se